INVOKANA ® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news